Literature DB >> 7396454

Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.

S Z Wilson, V Knight, P R Wyde, S Drake, R B Couch.   

Abstract

Ribavirin, amantadine, and the two drugs in combination given in small-particle aerosol were highly effective in the treatment of influenza A infection in mice. Treatment was started 72, 96, and 120 h after inoculation and was given continuously for 4 days. With increasing delay in start of treatment, there was a pronounced reduction in effectiveness of ribavirin but not in that of amantadine. The combination treatment reflected the loss of ribavirin activity. Leukocyte infiltration and virus titers in the lungs were inversely related to the effectiveness of treatment. Influenza B infection treated 72 h after inoculation responded only to ribavirin, as indicated by the criteria described for influenza A. Intraperitoneal administration of drug begun 72 h after inoculation in regimens equivalent to aerosol afforded less protection than aerosol treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7396454      PMCID: PMC283845          DOI: 10.1128/AAC.17.4.642

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Combined action of ribovirin and rimantadine in experimental myxovirus infection.

Authors:  G A Galegov; N L Pushkarskaya; N P Obrosova-Serova; V M Zhdanov
Journal:  Experientia       Date:  1977-07-15

2.  Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice.

Authors:  J S Walker; E L Stephen; R O Spertzel
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

3.  Amantadine small-particle aerosol: generation and delivery to man.

Authors:  S Z Wilson; V Knight; R Moore; E W Larson
Journal:  Proc Soc Exp Biol Med       Date:  1979-07

4.  Measurement of respiratory volume for virus retention studies in mice.

Authors:  G A Fairchild
Journal:  Appl Microbiol       Date:  1972-11

5.  Continuous aerosol therapy system using a modified Collison nebulizer.

Authors:  H W Young; J W Dominik; J S Walker; E W Larson
Journal:  J Clin Microbiol       Date:  1977-02       Impact factor: 5.948

6.  Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses.

Authors:  A L Frank; R B Couch; C A Griffis; B D Baxter
Journal:  J Clin Microbiol       Date:  1979-07       Impact factor: 5.948

7.  Inhibition of in vitro proliferative responses of human lymphocytes by rimantadine hydrochloride.

Authors:  W C Koff; D L Peavy; V Knight
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

8.  Gas-chromatographic determination of amantadine in human urine.

Authors:  M J Stumph; M W Noall; V Knight
Journal:  Clin Chem       Date:  1980-02       Impact factor: 8.327

9.  Amantadine aerosol in humans.

Authors:  V Knight; K Bloom; S Z Wilson; R K Wilson
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  Morphological and cytochemical characterization of cells infiltrating mouse lungs after influenza infection.

Authors:  P R Wyde; D L Peavy; T R Cate
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

  10 in total
  32 in total

1.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt.

Authors:  J M Colacino; D C DeLong; J R Nelson; W A Spitzer; J Tang; F Victor; C Y Wu
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections.

Authors:  P R Wyde; D K Moore-Poveda; E De Clercq; J Neyts; A Matsuda; N Minakawa; E Guzman; B E Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract.

Authors:  R J Fenton; P J Morley; I J Owens; D Gower; S Parry; L Crossman; T Wong
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 5.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

6.  Pharmacokinetics of ribavirin aerosol in mice.

Authors:  B E Gilbert; P R Wyde
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

7.  Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo.

Authors:  S Shigeta; S Mori; J Watanabe; S Soeda; K Takahashi; T Yamase
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

8.  In vivo inhibition of respiratory syncytial virus by ribavirin.

Authors:  J F Hruska; P E Morrow; S C Suffin; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

9.  Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro.

Authors:  F G Hayden; A N Schlepushkin; N L Pushkarskaya
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

10.  Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus.

Authors:  B E Gilbert; P R Wyde; S Z Wilson; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.